XORTX Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for XORTX Therapeutics (XRTX).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$70Upside to Avg. PT+6566.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 4, 2024	Alliance Global Partners	James Molloy	PT Raise	Buy	$45→$70

Analyst Ratings News

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Alliance Global Partners analyst James Molloy maintains XORTX Therapeutics (NASDAQ:XRTX) with a Buy and raises the price target from $9 to $14.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.

Benzinga Insights

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Alliance Global Partners analyst James Molloy initiates coverage on XORTX Therapeutics (NASDAQ:XRTX) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Benzinga

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

Benzinga

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

Benzinga

XORTX Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

XORTX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

People Also Watch

People Also Watch

XORTX Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

XORTX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAlliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

PROAlliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

People Also Watch

People Also Watch

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11